Tacrolimus for the treatment of atopic dermatitis

Faizullina E.V.; Fayzullin V.A.; Faĭzullin Ia.V.

doi:https://doi.org/

Faizullina E.V.

GBOU VPO "Kazanskiĭ gosudarstvennyĭ meditsinskiĭ universitet" MZ SR RF

ORCID: 0000-0002-5918-2596

Fayzullin V.A.

OOO "Tsentr Dermatologiia", Kazan'

ORCID: 0000-0003-4192-5395

Faĭzullin Ia.V.

GBOU VPO "Kazanskiĭ gosudarstvennyĭ meditsinskiĭ universitet" MZ SR RF

Tacrolimus for the treatment of atopic dermatitis

Authors:

Faizullina E.V., Fayzullin V.A., Faĭzullin Ia.V.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2012;10(3): 56‑61

Read: 17095 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Faizullina EV, Fayzullin VA, Faĭzullin IaV. Tacrolimus for the treatment of atopic dermatitis. Russian Journal of Clinical Dermatology and Venereology. 2012;10(3):56‑61. (In Russ.)

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)

Использование инфографики авторами научных работ

References:

Atopicheskii dermatit: novye podkhody k profilaktike i naruzhnoi terapii. Rekomendatsii dlya vrachei. Pod red. Yu.V. Sergeeva. M: Meditsina dlya vsekh 2005; 64.
Batyrshina S.V., Khaertdinova L.A. Atopicheskii dermatit: kompleksnaya diagnostika (kliniko-laboratornye kriterii i indeksy). Kazan': Brig 2010; 74.
Dermatovenerologiya. Klinicheskie rekomendatsii (Rossiiskoe obshchestvo dermatovenerologov). Pod red. A.A. Kubanovoi. M: DEKS-Press 2010; 428.
Kubanova A.A., Martynov A.A., Butareva M.M. Statsionarzameshchayushchie tekhnologii v okazanii spetsializirovannoi meditsinskoi pomoshchi bol'nym dermatozami. Vestn dermatol i venerol 2011; 2: 8-17.
Matushevskaya E.V., Svishchevskaya E.V. Topicheskie glyukokortikosteroidy v dermatologii. M 2010; 36.
Macharadze D.Sh. Atopicheskii dermatit: sovremennye metody diagnostiki i terapii. Uchebno-metodicheskoe posobie. M: izd-vo "Liniya-Print" 2011; 76.
Nesteroidnye protivovospalitel'nye sredstva v mestnom lechenii atopicheskogo dermatita u detei. Posobie dlya vrachei. Pod red. N.P. Shabalova, V.I. Kocherovtsa. SPb: RIA-AMI 2004; 24.
Sovremennaya strategiya naruzhnoi terapii pri atopicheskom dermatite u detei. Posobie dlya vrachei. M: Mezhdunarodnyi fond okhrany zdorov'ya materi i rebenka 2005; 44.
Abou-Jaoude M.M., Naim R., Shaheen J. et al. Tacrolimus (FK506) versus cyclosporin microemulsion (neoral) as maintenance immunosuppresion therapy in kidney transplant recipients. Transplant Proc 2005; 37: 7: 3025-3028.
Baumgart D.C., Pintoffl J.P., Sturm A. et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease-a long-term follow-up. Am J Gastroenterol 2006; 101: 5: 1048-1056.
Baumgart D.C., Silverberg N.B., Lin P. et al. Tacrolimus ointment promotes repigmentation of viiligo in children: a review of 57 cases. J Am Acad Dermatol 2004; 51: 5: 760-766.
Fukatsu S., Fukudo M., Masuda S. et al. Delayed effect of grapefruit juice on pharmacokinetics and pharmacodynamics of tacrolimus in a living-donor liver transplant recipient. Drug Metab Pharmacokin 2006; 21: 2: 122-125.
Hanifin J.M., Paller A.S., Eichenfield L. et al.; US Tacrolimus Ointment Study Group. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol 2005; 53: 2: Suppl ): S186-S194.
Miwa Y., Isozaki T., Wakabayashi K. et al. Tacrolimus-induced lung injury in a rheumatoid arthritis patient with interstitial pneumonitis. Mod Rheumatol 2008; 18: 2: 208-211.
Pritchard D. Sourcing a chemical succession for cyclosporin from parasites and human pathogens. Drug Disc Today 2005; 10: 10: 688-691.
William F. Ganong. Review of medical physiology (22nd ed.). Lange medical books. New York 2007; 530.
Zuberbier T., Chong S.U., Grunow K. et al. The ascomycin macrolactam pimecrolimus (elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human mast cells and peripheral blood basophils. J Allergy Clin Immunol 2001; 108: 275-280.
Paller A., Eichenfield L.F., Leung D.Y.M. et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44: S47-S57.
Hanifin J.M. Use of tacrolimus ointment (TO) in 3-6 year olds with atopic dermatitis (AD): Dose-escalation study. J Invest Dermatol 1998; 110: 680.
Kang S., Lucky A.W., Pariser D. et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44: S58-S64.
Reitamo S., Harper J., Bos J.D. et al. 0,03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol 2004; 150: 3: 554-562.
Doss N., Kamoun M.-R., Dubertret L. et al. Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0,005% ointment. Pediatr Allergy Immunol 2010; 21: 2: Pt 1: 321-329.
Paller A.S., Lebwohl M., Fleischer A.B. Jr et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 2005; 52: 5: 810-822.
Wollenberg A., Reitamo S., Atzori F. et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008; 63: 742-750.
Thaci D., Reitamo S., Gonzalez Ensenat M.A. et al. Proactive disease management with 0,03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol 2008; 159: 6: 1348-1356.
Mandelin J.M., Rubins A., Remitz A. et al. Long-term efficacy and tolerability of tacrolimus 0.03% ointment in infants: a two-year open-label study. Int J Dermatol 2012; 51: 1: 104-110.
Reitamo S., Allsopp R. Treatment with twice-weekly tacrolimus ointment in patients with moderate to severe atopic dermatitis: results from two randomized, multicenter, comparative studies. J Dermatol Treat 2010; 21: 34-44.